182 related articles for article (PubMed ID: 32825821)
1. Cherubism as a systemic skeletal disease: evidence from an aggressive case.
Morice A; Joly A; Ricquebourg M; Maruani G; Durand E; Galmiche L; Amiel J; Vial Y; Cavé H; Belhous K; Piketty M; Cohen-Solal M; Berdal A; Collet C; Picard A; Coudert AE; Kadlub N
BMC Musculoskelet Disord; 2020 Aug; 21(1):564. PubMed ID: 32825821
[TBL] [Abstract][Full Text] [Related]
2. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
3. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
4. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
5. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
6. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.
Yoshitaka T; Kittaka M; Ishida S; Mizuno N; Mukai T; Ueki Y
Bone; 2015 Feb; 71():201-9. PubMed ID: 25445458
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the SH3BP2 gene in 2 families of cherubism.
Tuna EB; Shimizu T; Seymen F; Yildirim M; Gencay K; Maeda T
Pediatr Dent; 2012; 34(3):198-202. PubMed ID: 22795151
[TBL] [Abstract][Full Text] [Related]
9. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
10. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
11. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
12. A novel mutation in the SH3BP2 gene causes cherubism: case report.
Li CY; Yu SF
BMC Med Genet; 2006 Dec; 7():84. PubMed ID: 17147794
[TBL] [Abstract][Full Text] [Related]
13. Cherubism: a systematic literature review of clinical and molecular aspects.
Chrcanovic BR; Guimarães LM; Gomes CC; Gomez RS
Int J Oral Maxillofac Surg; 2021 Jan; 50(1):43-53. PubMed ID: 32620450
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
15. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism.
Carvalho VM; Perdigão PF; Pimenta FJ; de Souza PE; Gomez RS; De Marco L
Oral Oncol; 2008 Feb; 44(2):153-5. PubMed ID: 17368082
[TBL] [Abstract][Full Text] [Related]
16. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
17. Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw.
Idowu BD; Thomas G; Frow R; Diss TC; Flanagan AM
Br J Oral Maxillofac Surg; 2008 Apr; 46(3):229-230. PubMed ID: 17544554
[TBL] [Abstract][Full Text] [Related]
18. Novel nucleotide mutation leading to a recurrent amino acid alteration in SH3BP2 in a patient with cherubism.
Sangu N; Shimosato T; Inoda H; Shimada S; Shimojima K; Ando T; Yamamoto T
Congenit Anom (Kyoto); 2013 Dec; 53(4):166-9. PubMed ID: 24712477
[TBL] [Abstract][Full Text] [Related]
19. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
20. Imatinib has minimal effects on inflammatory and osteopenic phenotypes in a murine cherubism model.
Mukai T; Akagi T; Hiramatsu Asano S; Tosa I; Ono M; Kittaka M; Ueki Y; Yahagi A; Iseki M; Oohashi T; Ishihara K; Morita Y
Oral Dis; 2023 Apr; 29(3):1089-1101. PubMed ID: 34743383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
